Results 151 to 160 of about 2,872,365 (306)

Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review

Addiction, EarlyView.
Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its
Theodore Piper, Francesca Small, Sam Brown, Michael Kelleher, Luke Mitcheson, James Rucker, Allan H. Young, John Marsden   +7 more
wiley   +1 more source

Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study

Addiction, EarlyView.
Abstract Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we assessed the safety and feasibility of outpatient psilocybin‐assisted psychotherapy for methamphetamine use disorder. Design Single arm, open label pilot study.
Elizabeth Knock, Krista J. Siefried, Gill Bedi, Steven Albert, Richard O. Day, Nadine Ezard, Margaret Ross, Paul Liknaitzky, Jonathan Brett   +8 more
wiley   +1 more source

Varenicline for cannabis use disorder: A randomized controlled trial

Addiction, EarlyView.
Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark, Kevin M. Gray, Nathaniel L. Baker, Brian J. Sherman, Bryan Tolliver, Jessica Burt, Alonzo Steplight, Elizabeth Chapman, Amanda Wagner   +8 more
wiley   +1 more source

Current and future options for opioid use disorder: a survey assessing real-world opinion of service users on novel therapies including depot formulations of buprenorphine

Patient Preference and Adherence, 2018
Mark Gilman,1 Li Li,2 Kerrie Hudson,3 Tara Lumley,2 Georgia Myers,2 Camilla Corte,2 Richard Littlewood2 1Discovering Health, Manchester, UK; 2Applied Strategic, London, UK; 3The Well Communities CIC, Lancaster, UK Purpose: Integrated treatment for ...
Gilman M, Li L, Hudson K, Lumley T, Myers G, Corte C, Littlewood R   +6 more
doaj  

Comparative effectiveness, safety and acceptability of pharmacological and psychosocial interventions for the treatment of cannabis use disorder: A network meta‐analysis

Addiction, EarlyView.
Abstract Aim Our primary aim was to conduct a network meta‐analysis (NMA) for the effectiveness, safety and acceptability of all psychosocial interventions and all pharmacotherapies for cannabis use disorder (CUD). Methods We conducted a NMA of studies identified from two completed systematic reviews examining the effectiveness, safety and ...
Monika Halicka, Francesca Spiga, Tom P. Freeman, Suzanne Nielsen, Jelena Savović, Julian P. T. Higgins, Deborah M. Caldwell   +6 more
wiley   +1 more source

Use of Opioid Agonist Therapy for Medicare Patients in 2013 [PDF]

JAMA Psychiatry, 2016
Anna, Lembke, Jonathan H, Chen
openaire   +2 more sources

Beyond abstinence: Redefining success in cannabis use disorder treatment

Addiction, EarlyView.
Abstract Background Over two decades of pharmacotherapy research has yet to yield a consistently effective medication for cannabis use disorder (CUD), in part because clinical trials have frequently prioritized abstinence as a primary or key endpoint.
Tobias B. Atkin, Frances R. Levin, John Mariani, Christina A. Brezing   +3 more
wiley   +1 more source

Transition from methadone to subcutaneous buprenorphine depot in patients with opioid use disorder - a case report

European Psychiatry
Introduction Opioid dependence is a complex condition that often requires long-term treatment and care. Methadone, a synthetic full opioid agonist, and buprenorphine, a partial agonist at the opioid receptor, are most commonly used for substitution ...
M. Delic
doaj   +1 more source

The impact of harm reduction interventions on injection‐related bacterial infections among people who inject drugs: A systematic review

Addiction, EarlyView.
Abstract Background and aims Injection‐related bacterial infections represent a major but under‐recognised health issue among people who inject drugs (PWID). Harm reduction interventions (HRIs) like needle and syringe programmes (NSP) and opioid agonist treatment (OAT) could mitigate their burden.
Anthony Cousien, Lobna Tijani, Nadia Hachicha, Manon Godart, Mathieu Castry, Karen Champenois, Perrine Roux, Sylvie Deuffic‐Burban   +7 more
wiley   +1 more source

Oral Combination of Vitamin B1, B6, and B12 Supplementation on CD4+ T Cell and IFN-γ in Pulmonary Tuberculosis Patients with First-Line Opioid agonist therapy

, 2023
Introduction: Tuberculosis (TB) is a wasting or consumption disease which causes metabolic changes in tuberculosis patients. The metabolic changes that can occur are decreased appetite, micronutrient malabsorption, and malnutrition.
Sulaeman, Sulaeman, Abror, Yogi Khoirul, Wiryanti, Wiwin   +2 more
core